Association between TML and time-to-first treatment among individuals with HCMBL
| CLL-IPI . | Mutated genes . | Total . | Event . | HR . | 95% CI . | P value . | |
|---|---|---|---|---|---|---|---|
| N . | col % . | N . | |||||
| Overall∗ | None | 147 | 51.0 | 9 | 1.00 | Reference | |
| (N = 288) | Any | 141 | 49.0 | 48 | 5.37 | (2.63-10.98) | <.0001 |
| 0 | 147 | 51.0 | 9 | 1.00 | Reference | ||
| 1 | 90 | 31.3 | 31 | 5.30 | (2.51-11.21) | <.0001 | |
| ≥2 | 51 | 17.7 | 17 | 5.50 | (2.44-12.36) | <.0001 | |
| Cont. | 288 | 100 | 56 | 1.59 | (1.33-1.89) | <.0001 | |
| c-statistic | 0.726 | (0.65-0.80) | |||||
| Low-risk CLL-IPI† | None | 103 | 57.5 | 5 | 1.00 | Reference | |
| (n = 179) | Any | 76 | 42.5 | 18 | 4.30 | (1.57-11.79) | .005 |
| 0 | 103 | 57.5 | 5 | 1.00 | Reference | ||
| 1 | 56 | 31.3 | 14 | 4.47 | (1.56-12.77) | .005 | |
| ≥2 | 20 | 11.2 | 4 | 3.88 | (1.04-14.47) | .043 | |
| Cont. | 179 | 100 | 23 | 1.75 | (1.15-2.68) | .009 | |
| c-statistic | 0.660 | (0.56-0.76) | |||||
| Intermediate-risk CLL-IPI† | None | 27 | 38.6 | 4 | 1.00 | Reference | |
| (n = 70) | Any | 43 | 61.4 | 20 | 3.04 | (1.02-9.01) | .045 |
| 0 | 27 | 38.6 | 4 | 1.00 | Reference | ||
| 1 | 23 | 32.9 | 11 | 3.51 | (1.11-11.14) | .033 | |
| ≥2 | 20 | 28.6 | 9 | 2.57 | (0.77-8.55) | .123 | |
| Cont. | 70 | 100 | 24 | 1.48 | (1.04-2.11) | .028 | |
| c-statistic | 0.650 | (0.54-0.76) | |||||
| High- to very high–risk CLL-IPI† | None | 24 | 52.2 | 0 | 1.00 | Reference | |
| (n = 46) | Any | 22 | 57.8 | 9 | NA | NA | NA |
| 0 | 24 | 52.2 | 0 | 1.00 | Reference | ||
| 1 | 11 | 23.9 | 5 | NA | NA | NA | |
| ≥2 | 11 | 23.9 | 4 | NA | NA | NA | |
| Cont. | 46 | 100 | 9 | 1.48 | (1.07-2.07) | .019 | |
| c-statistic | 0.803 | (0.71-0.90) | |||||
| CLL-IPI . | Mutated genes . | Total . | Event . | HR . | 95% CI . | P value . | |
|---|---|---|---|---|---|---|---|
| N . | col % . | N . | |||||
| Overall∗ | None | 147 | 51.0 | 9 | 1.00 | Reference | |
| (N = 288) | Any | 141 | 49.0 | 48 | 5.37 | (2.63-10.98) | <.0001 |
| 0 | 147 | 51.0 | 9 | 1.00 | Reference | ||
| 1 | 90 | 31.3 | 31 | 5.30 | (2.51-11.21) | <.0001 | |
| ≥2 | 51 | 17.7 | 17 | 5.50 | (2.44-12.36) | <.0001 | |
| Cont. | 288 | 100 | 56 | 1.59 | (1.33-1.89) | <.0001 | |
| c-statistic | 0.726 | (0.65-0.80) | |||||
| Low-risk CLL-IPI† | None | 103 | 57.5 | 5 | 1.00 | Reference | |
| (n = 179) | Any | 76 | 42.5 | 18 | 4.30 | (1.57-11.79) | .005 |
| 0 | 103 | 57.5 | 5 | 1.00 | Reference | ||
| 1 | 56 | 31.3 | 14 | 4.47 | (1.56-12.77) | .005 | |
| ≥2 | 20 | 11.2 | 4 | 3.88 | (1.04-14.47) | .043 | |
| Cont. | 179 | 100 | 23 | 1.75 | (1.15-2.68) | .009 | |
| c-statistic | 0.660 | (0.56-0.76) | |||||
| Intermediate-risk CLL-IPI† | None | 27 | 38.6 | 4 | 1.00 | Reference | |
| (n = 70) | Any | 43 | 61.4 | 20 | 3.04 | (1.02-9.01) | .045 |
| 0 | 27 | 38.6 | 4 | 1.00 | Reference | ||
| 1 | 23 | 32.9 | 11 | 3.51 | (1.11-11.14) | .033 | |
| ≥2 | 20 | 28.6 | 9 | 2.57 | (0.77-8.55) | .123 | |
| Cont. | 70 | 100 | 24 | 1.48 | (1.04-2.11) | .028 | |
| c-statistic | 0.650 | (0.54-0.76) | |||||
| High- to very high–risk CLL-IPI† | None | 24 | 52.2 | 0 | 1.00 | Reference | |
| (n = 46) | Any | 22 | 57.8 | 9 | NA | NA | NA |
| 0 | 24 | 52.2 | 0 | 1.00 | Reference | ||
| 1 | 11 | 23.9 | 5 | NA | NA | NA | |
| ≥2 | 11 | 23.9 | 4 | NA | NA | NA | |
| Cont. | 46 | 100 | 9 | 1.48 | (1.07-2.07) | .019 | |
| c-statistic | 0.803 | (0.71-0.90) | |||||